Pu LY - Search Results

1

Correction: Formal synthesis of cyclotheonellazole A.

Long B, Pu LY, Liu Z, Zeng X, Wu Z. Long B, et al. Among authors: pu ly. Org Biomol Chem. 2023 May 10;21(18):3906. doi: 10.1039/d3ob90065g. Org Biomol Chem. 2023. PMID: 37115103

2

Efficient synthesis of novel colchicine-magnolol hybrids and evaluation of their inhibitory activity on key proteases of 2019-nCoV replication and acute lung injury.

Pu LY, Li Z, Huang F, Li L, Ma Y, Ma M, Hu S, Wu Z. Pu LY, et al. Nat Prod Res. 2024 Apr;38(7):1238-1247. doi: 10.1080/14786419.2022.2138870. Epub 2022 Oct 27. Nat Prod Res. 2024. PMID: 36302171

3

Design, synthesis and biological evaluation of a novel colchicine-magnolol hybrid for inhibiting the growth of Lewis lung carcinoma in Vitro and in Vivo.

Li Z, Hu S, Pu LY, Li Z, Zhu G, Cao Y, Li L, Ma Y, Liu Z, Li X, Liu G, Chen K, Wu Z. Li Z, et al. Among authors: pu ly. Front Chem. 2022 Dec 13;10:1094019. doi: 10.3389/fchem.2022.1094019. eCollection 2022. Front Chem. 2022. PMID: 36583151 Free PMC article.

4

Concise Enantioselective Total Synthesis of Isopavine Alkaloids.

Pu LY, Li Z, Li L, Ma Y, Hu S, Wu Z. Pu LY, et al. J Org Chem. 2023 Apr 7;88(7):4317-4324. doi: 10.1021/acs.joc.2c02899. Epub 2023 Mar 9. J Org Chem. 2023. PMID: 36893742

5

Formal synthesis of cyclotheonellazole A.

Long B, Pu L, Liu Z, Zeng X, Wu Z. Long B, et al. Org Biomol Chem. 2023 May 3;21(17):3531-3536. doi: 10.1039/d3ob00038a. Org Biomol Chem. 2023. PMID: 37039531

6

Design, synthesis and evaluation of a myricetin and nobiletin hybrid compound for alleviating hyperuricemia based on metabolomics and gut microbiota.

Li Y, Pu LY, Li Y, Zhu G, Wu Z. Li Y, et al. Among authors: pu ly. RSC Adv. 2023 Jul 17;13(31):21448-21458. doi: 10.1039/d3ra03188h. eCollection 2023 Jul 12. RSC Adv. 2023. PMID: 37465570 Free PMC article.

7

A novel colchicine-myricetin heterozygous molecule: design, synthesis, and effective evaluations on the pathological models of acute lung injury in vitro and in vivo.

Li Z, Yan X, Wei J, Pu L, Zhu G, Cao Y, Liu Z, Liu Y, Li Y, Li L, Li X, Wu Z. Li Z, et al. Front Pharmacol. 2023 Jun 29;14:1224906. doi: 10.3389/fphar.2023.1224906. eCollection 2023. Front Pharmacol. 2023. PMID: 37456754 Free PMC article.

8

[Surgical treatment and prognosis analysis of hilar cholangiocarcinoma].

Li XC, Li CX, Zhang H, Cheng F, Zhang F, Pu LY, Zhang CY, Wang K, Kong LB, Qian XF, Li DH, Lu WX, Wang P, Yao AH, Bai JF, Wu XF, Chen RX, Wang XH. Li XC, et al. Among authors: pu ly. Zhonghua Wai Ke Za Zhi. 2024 Apr 1;62(4):290-301. doi: 10.3760/cma.j.cn112139-20231221-00296. Zhonghua Wai Ke Za Zhi. 2024. PMID: 38432670 Chinese.

9

Chiral phosphoric acid-catalyzed dual-ring formation for enantioselective construction of N-N axially chiral 3,3'-bisquinazolinones.

Pu LY, Zhang YJ, Liu W, Teng F. Pu LY, et al. Chem Commun (Camb). 2022 Nov 24;58(94):13131-13134. doi: 10.1039/d2cc05172a. Chem Commun (Camb). 2022. PMID: 36349690

10

[Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma].

Xia YX, Zhang H, Zhang F, Li XC, Rong DW, Tang WW, Cao HS, Zhao J, Wang P, Pu LY, Qian XF, Cheng F, Wang K, Kong LB, Zhang CY, Li DH, Song JH, Yao AH, Wu XF, Wu C, Wang XH. Xia YX, et al. Among authors: pu ly. Zhonghua Wai Ke Za Zhi. 2022 Jul 1;60(7):688-694. doi: 10.3760/cma.j.cn112139-20220408-00150. Zhonghua Wai Ke Za Zhi. 2022. PMID: 35775262 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page